Etoposide
Etopophos, Etoposide (etoposide) is a small molecule pharmaceutical. Etoposide was first approved as Vepesid on 1983-11-10. It is used to treat brain neoplasms, ewing sarcoma, histiocytosis, kaposi sarcoma, and lung neoplasms amongst others in the USA. The pharmaceutical is active against DNA topoisomerase 2-alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Etopophos, Etoposide (discontinued: Etopophos, Etoposide, Toposar, Vepesid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etoposide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VEPESID | CordenPharma | N-018768 DISCN | 1983-11-10 | 1 products, RLD |
| VEPESID | Strides Pharma Global | N-019557 DISCN | 1986-12-30 | 2 products, RLD |
Hide discontinued
Etoposide phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ETOPOPHOS PRESERVATIVE FREE | CHEPLAPHARM Arzneimittel | N-020457 RX | 1996-05-17 | 1 products, RLD, RS |
Show 1 discontinued
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
1851 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 130 | 386 | 104 | 18 | 38 | 602 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 80 | 195 | 79 | 4 | 23 | 338 |
| Leukemia | D007938 | — | C95 | 93 | 157 | 92 | 6 | 23 | 324 |
| Small cell lung carcinoma | D055752 | — | — | 69 | 170 | 68 | 3 | 21 | 294 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 60 | 141 | 33 | 5 | 8 | 211 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 32 | 75 | 42 | 9 | 14 | 152 |
| B-cell lymphoma | D016393 | — | — | 54 | 90 | 21 | 2 | 7 | 146 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 46 | 86 | 19 | 1 | 7 | 136 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 41 | 54 | 40 | 1 | 12 | 131 |
| Neoplasms | D009369 | — | C80 | 54 | 58 | 18 | 1 | 9 | 127 |
Show 25 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia | D007951 | — | C92 | 39 | 53 | 37 | — | 13 | 126 |
| Carcinoma | D002277 | — | C80.0 | 16 | 52 | 16 | — | 3 | 77 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 19 | 34 | 21 | — | 5 | 75 |
| Recurrence | D012008 | — | — | 29 | 45 | 6 | — | 6 | 72 |
| Multiple myeloma | D009101 | — | C90.0 | 12 | 44 | 10 | — | 6 | 68 |
| Sarcoma | D012509 | — | — | 13 | 34 | 17 | — | 6 | 67 |
| Plasma cell neoplasms | D054219 | — | — | 9 | 39 | 9 | — | 4 | 59 |
| Myelodysplastic syndromes | D009190 | — | D46 | 22 | 25 | 13 | — | 3 | 55 |
| Central nervous system neoplasms | D016543 | — | — | 9 | 28 | 7 | — | 5 | 48 |
| Preleukemia | D011289 | — | — | 18 | 19 | 13 | — | 2 | 45 |
Show 117 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 7 | 15 | — | — | 5 | 24 |
| Plasmacytoma | D010954 | — | C90.3 | 6 | 15 | — | — | 2 | 23 |
| Hematologic neoplasms | D019337 | — | — | 7 | 7 | — | — | 3 | 16 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 5 | 7 | — | — | 3 | 12 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | 3 | 8 | — | — | 1 | 12 |
| Graft vs host disease | D006086 | — | D89.81 | 3 | 7 | — | — | 3 | 12 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 3 | 6 | — | — | 2 | 10 |
| Lymphomatoid granulomatosis | D008230 | — | C83.8 | 4 | 4 | — | — | 3 | 9 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 3 | 6 | — | — | — | 9 |
| T-cell lymphoma cutaneous | D016410 | — | — | 4 | 2 | — | — | 3 | 8 |
Show 129 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Large granular lymphocytic leukemia | D054066 | — | — | 2 | — | — | — | 2 | 4 |
| Neuroepithelial neoplasms | D018302 | — | — | 2 | — | — | — | — | 2 |
| Pharyngeal neoplasms | D010610 | — | C14.0 | 2 | — | — | — | — | 2 |
| Peritoneal neoplasms | D010534 | — | — | 2 | — | — | — | — | 2 |
| Melanoma | D008545 | — | — | 2 | — | — | — | — | 2 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | — | — | — | — | 1 |
| Deltaretrovirus infections | D006800 | EFO_1001303 | — | 1 | — | — | — | — | 1 |
| Htlv-i infections | D015490 | EFO_0007316 | — | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chediak-higashi syndrome | D002609 | Orphanet_167 | D72.0 | — | — | — | — | 2 | 2 |
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | — | — | — | 1 | 1 |
| Hemoglobinuria | D006456 | — | R82.3 | — | — | — | — | 1 | 1 |
| Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 1 | 1 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
| Peripheral blood stem cell transplantation | D036102 | — | — | — | — | — | — | 1 | 1 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etoposide |
| INN | etoposide |
| Description | Etoposide is a beta-D-glucoside, a furonaphthodioxole and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4'-demethylepipodophyllotoxin. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O |
Identifiers
| PDB | — |
| CAS-ID | 33419-42-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL44657 |
| ChEBI ID | 4911 |
| PubChem CID | 36462 |
| DrugBank | DB00773 |
| UNII ID | 6PLQ3CP4P3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TOP2B
TOP2B
Organism
Homo sapiens
Gene name
TOP2B
Gene synonyms
NCBI Gene ID
Protein name
DNA topoisomerase 2-beta
Protein synonyms
antigen MLAA-44, DNA topoisomerase II, 180 kD, DNA topoisomerase II, beta isozyme, topo II beta, topoisomerase (DNA) II beta 180kDa, topoisomerase II beta, topoisomerase IIb, U937 associated antigen
Uniprot ID
Mouse ortholog
Top2b (21974)
DNA topoisomerase 2-beta (Q7TQG4)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Etoposide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 70,182 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
58,635 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use